Abivax SA Sponsored ADR $ABVX Shares Purchased by Jennison Associates LLC

Jennison Associates LLC lifted its holdings in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 64.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 210,534 shares of the company’s stock after purchasing an additional 82,627 shares during the period. Jennison Associates LLC’s holdings in Abivax were worth $23,443,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. GHP Investment Advisors Inc. grew its holdings in Abivax by 155.6% in the first quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock valued at $26,000 after purchasing an additional 140 shares during the period. Caitong International Asset Management Co. Ltd raised its stake in shares of Abivax by 661.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after buying an additional 344 shares during the period. T. Rowe Price Investment Management Inc. acquired a new position in shares of Abivax during the 4th quarter worth approximately $61,000. WPG Advisers LLC lifted its position in shares of Abivax by 125.9% during the 4th quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after buying an additional 253 shares in the last quarter. Finally, Union Bancaire Privee UBP SA purchased a new position in shares of Abivax during the 4th quarter valued at approximately $67,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Price Performance

ABVX stock opened at $131.50 on Tuesday. Abivax SA Sponsored ADR has a 1 year low of $9.95 and a 1 year high of $148.83. The firm has a market capitalization of $11.46 billion, a PE ratio of -25.24 and a beta of 0.87. The business has a 50 day simple moving average of $117.16 and a 200-day simple moving average of $118.26.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.23. The company had revenue of $1.56 million for the quarter, compared to analysts’ expectations of $0.40 million. On average, equities research analysts expect that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ABVX. Truist Financial boosted their price target on shares of Abivax from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. Wedbush increased their price objective on shares of Abivax from $90.00 to $110.00 and gave the company a “neutral” rating in a report on Tuesday, June 30th. HC Wainwright reissued a “buy” rating on shares of Abivax in a research note on Tuesday, June 30th. Guggenheim restated a “buy” rating on shares of Abivax in a research report on Tuesday, June 30th. Finally, Leerink Partners raised their price target on shares of Abivax from $140.00 to $148.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th. Fourteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Abivax has an average rating of “Moderate Buy” and a consensus price target of $148.54.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.